The round was led by an undisclosed strategic investor, with participation from Edge Medical Ventures, SHD Partners, Longevity Venture Partners, and additional healthcare-focused investors. The funding will support the company's clinical validation, FDA 510(k) regulatory pathway, and initial U.S. commercialization efforts.

Urologic Health is a medical device company developing non-invasive diagnostic technology for bladder function assessment. Its niu™ System is designed to capture bladder activity as clinically meaningful diagnostic data without catheterization, supporting more routine and repeatable urodynamic assessment. The company was co-founded by Adam Yaacov and Dr. Noam Omer, who bring expertise in developing innovative medical technologies that advance healthcare through AI-driven insights and data-centric clinical solutions. Urologic Health was founded and incubated at the MEDX Xelerator venture studio (now EdgeLabs) and operates as part of the Edge Medical Ventures portfolio, with operations in the United States and Israel.